Lek once again among the most reputable employers in Slovenia

9. 3. 2016

For the fifth time in a row, the recruitment portal MojeDelo.com has conducted a survey about the reputation of Slovenian employers. As in previous years, this year again Lek, a Sandoz company, is among the most reputable employers and received the Reputable Employer award.

The extensive online survey checks among candidates in the labour market as to which employers are most attractive for them and which represent the first choice for job seekers.

The reputation of an employer is determined with the help of a quotient which is based on the company’s visibility, considering the organisation as a potential employer among the candidates and being the employee’s first choice of potential employer.

»The fact that our candidates on the labour market have been placing us for all these years among the most respected employers in Slovenia confirms, that Lek, a Sandoz company, successfully builds a motivational and quality working environment. This is extremely important, as it is the only way to attract top talents which is crucial in a highly competitive and knowledge-based industry such as pharmacy. Motivated employees with high-quality knowledge are a guarantee for our long-term development,« said Samo Roš, Member of the Lek Management Board and Head of Human Resources at Lek, a Sandoz company, upon receiving the award.

In the last four years, Lek, a Sandoz company, has created more than 1,100 new jobs in Slovenia. The company creates jobs with high added value, is the employer of choice and has a high degree of responsibility towards its employees as to others in the environment in which it operates.

* * *

Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit http://www.lek.si/en.

Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32